BioCentury

The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis:

[BioCentury @BioCentury]

The race to create a new Ebola vaccine. @CEPIvaccines' $60M+ funding commitment aims to advance Bundibugyo virus vaccines to the clinic as fast as possible. https://t.co/QVbJhPYDRq

[BioCentury @BioCentury]

In the third and largest acquisition of Luke Miels' brief tenure thus far as CEO, GSK is buying Nuvalent for $10.6B to gain two registration-stage therapies for targeted groups of lung cancer patients https://t.co/ZnVhVUkpUU

[BioCentury @BioCentury]

WuXi AppTec's listing as Chinese military company focuses attention Biosecure, additional measures aimed at reducing U.S. biopharmas' engagement with China. https://t.co/rMdSGo8P91

[BioCentury @BioCentury]

The latest #BioCenturyThisWeek podcast out now: New leaders set tone at @US_FDA; billion-dollar deals by @Servier, @Incyte, J&J pace biopharma BD. @JNJnews. This week with @SteveUsdin1 @FishburnSimone @StephenPHansen @Jeff_Cranmer. https://t.co/Bsc8DM5kO7

[BioCentury @BioCentury]

Eli Lilly dealmaking spree this year has seen it commit over $45B across 20 deals, with the majority of the capital directed at #autoimmune and #cancer deals, and only one focused on #obesity, and the majority of deals in research/preclinical stage $LLY https://t.co/qtyCQY3z1O

[BioCentury @BioCentury]

BioCentury's Deals Report features a pair of deals around protein degradation, as J&J buys Firefly and Roche works with Nurix https://t.co/MrEFsfvyMx

[BioCentury @BioCentury]

Incyte will gain a late-stage therapy for von Willebrand disease via its billion-dollar takeout of Vega, generating returns for shareholders of venture-backed parent company Star https://t.co/cz3ieje3Ce

[BioCentury @BioCentury]

FDA approved seven NMEs in May: A BioCentury Data Byte https://t.co/TzS1R6Uy45

[BioCentury @BioCentury]

In BioCentury's Finance Report: Ona's venture round among largest for a biotechin Spain; NewLimit's nine-figure raise; follow-ons for Jade, Mineralys; LongBio's Hong Kong IPO; and more https://t.co/PqqfiIUH0K

[BioCentury @BioCentury]

ADCs headline first-in-human development at #ASCO26: BioCentury’s analysis of 137 FIH studies highlighted at this year’s conference https://t.co/l5Hg9QXpVD

[BioCentury @BioCentury]

In BioCentury's latest Management Tracks: Former Novo exec joins Forbion as firm promotes two partners; plus changes at Airna, Myriad Genetics and Oncolytics https://t.co/iEdze75FFV

[BioCentury @BioCentury]

Fred Hutch’s Sylvain Simon crowned ‘Rising Star’ at Grand Rounds U.S. in Seattle for innovative chimeric T cell receptor platform. @FredHutch https://t.co/nDdRJfoOZI

[BioCentury @BioCentury]

Meeting with rare disease advocates is a sign of acting @US_FDA leadership trying to right the ship https://t.co/dEF5cZQq6N

[BioCentury @BioCentury]

Bipartisan bill seeks to limit U.S. in-licensing from China: Legislation exerts pressure on Trump administration to curtail biopharma engagement with China https://t.co/ejBz3w9yy6

[BioCentury @BioCentury]

French pharma #Servier is taking a page out of its oncology playbook to build out a neurology franchise, starting with the $1.6B acquisition of #sevasemten from Edgewise Therapeutics. BioCentury's @StephenPHansen speaks with Servier's David Lee https://t.co/efSfyzUDl2

[BioCentury @BioCentury]

Legend’s ex vivo design expertise underpins in vivo CAR T efficacy. In conversation with BioCentury's Lauren Martz, CEO Ying Huang discusses Legend's first-in-human in vivo CAR T results. https://t.co/yT35b1s8XX

[BioCentury @BioCentury]

BioCentury's Science Spotlight highlights microglial states as druggable nodes in CNS disease and an atlas of tertiary lymphoid structures https://t.co/tof3LamLPH

[BioCentury @BioCentury]

The benefits of @US_FDA reviewing trials in 'real time' are uncertain, but the process of making trials ready for real-time review could be transformative https://t.co/nfrvujC20t

[BioCentury @BioCentury]

Cancer cases cloud efficacy in Abivax colitis study https://t.co/uusBPaNjSy

[BioCentury @BioCentury]

.@AllenInstitute launches atlas-to-therapy push in neurodegeneration: Brain Health Accelerator, debuting with $400M, aims to turn cellular maps and disease data into precision gene therapies for neurodegeneration https://t.co/AAzPNjrCiX